Lantern Pharma Inc (LTRN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.47M
Last updated: Nov 17, 2026 at 11:01 AM ET
Lantern Pharma Inc (LTRN) Earnings: Report Dates and Results
Lantern Pharma (LTRN) is expected to report earnings on Nov 17, 2026. In the quarter ended Jun 30, 2026, Lantern Pharma reported EPS of -$0.28, above the -$0.38 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
LTRN has an expected report date of Nov 17, 2026.
LTRN Earnings Call
The latest LTRN earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 25 quarters below that had an estimate, LTRN beat 20 and missed 5. The widest gap in the table came in the quarter ended Sep 30, 2022, when EPS landed 56.25% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | -$0.28 | -$0.38 | -$0.38 - -$0.38 | +26.32% | Beat | N/A | 1 | 0 up, 0 down | Aug 14, 2026 |
| Mar 31, 2026 | -$0.30 | -$0.36 | -$0.36 - -$0.36 | +16.67% | Beat | N/A | 1 | 0 up, 0 down | May 15, 2026 |
| Dec 31, 2025 | -$0.36 | -$0.46 | -$0.46 - -$0.46 | +21.74% | Beat | N/A | 1 | 0 up, 0 down | Mar 30, 2026 |
| Sep 30, 2025 | -$0.39 | -$0.47 | -$0.47 - -$0.47 | +17.02% | Beat | N/A | 1 | 1 up, 0 down | Nov 12, 2025 |
| Jun 30, 2025 | -$0.40 | -$0.48 | -$0.53 - -$0.44 | +16.67% | Beat | N/A | 2 | 1 up, 0 down | Aug 13, 2025 |
| Mar 31, 2025 | -$0.42 | -$0.43 | N/A | +2.33% | Beat | N/A | 1 | 0 up, 0 down | May 15, 2025 |
| Dec 31, 2024 | -$0.54 | -$0.51 | -$0.51 - -$0.51 | -5.88% | Miss | N/A | 1 | 0 up, 1 down | Mar 27, 2025 |
| Sep 30, 2024 | -$0.42 | -$0.56 | -$0.56 - -$0.56 | +25.00% | Beat | N/A | 1 | 0 up, 0 down | Nov 7, 2024 |
| Jun 30, 2024 | -$0.46 | -$0.55 | -$0.55 - -$0.55 | +16.36% | Beat | N/A | 1 | 0 up, 0 down | Aug 8, 2024 |
| Mar 31, 2024 | -$0.51 | -$0.43 | -$0.43 - -$0.43 | -18.60% | Miss | N/A | 1 | 0 up, 0 down | May 9, 2024 |
| Dec 31, 2023 | -$0.39 | -$0.40 | -$0.48 - -$0.32 | +2.50% | Beat | N/A | 2 | 0 up, 0 down | Mar 18, 2024 |
| Sep 30, 2023 | -$0.29 | -$0.48 | -$0.48 - -$0.43 | +39.58% | Beat | N/A | 2 | 0 up, 0 down | Nov 8, 2023 |
| Jun 30, 2023 | -$0.44 | -$0.45 | -$0.51 - -$0.39 | +2.22% | Beat | N/A | 3 | 0 up, 0 down | Aug 9, 2023 |
| Mar 31, 2023 | -$0.36 | -$0.48 | -$0.48 - -$0.48 | +25.00% | Beat | N/A | 1 | 0 up, 0 down | May 9, 2023 |
| Dec 31, 2022 | -$0.31 | -$0.47 | -$0.49 - -$0.45 | +34.04% | Beat | N/A | 2 | 0 up, 0 down | Mar 20, 2023 |
| Sep 30, 2022 | -$0.21 | -$0.48 | -$0.54 - -$0.42 | +56.25% | Beat | N/A | 2 | 0 up, 0 down | Nov 7, 2022 |
| Jun 30, 2022 | -$0.41 | -$0.52 | -$0.52 - -$0.52 | +21.15% | Beat | N/A | 1 | 0 up, 0 down | Aug 8, 2022 |
| Mar 31, 2022 | -$0.38 | -$0.29 | -$0.29 - -$0.29 | -31.03% | Miss | N/A | 1 | 0 up, 0 down | May 3, 2022 |
| Dec 31, 2021 | -$0.32 | -$0.40 | -$0.43 - -$0.38 | +20.00% | Beat | N/A | 3 | 0 up, 0 down | Mar 10, 2022 |
| Sep 30, 2021 | -$0.36 | -$0.24 | -$0.31 - -$0.22 | -50.00% | Miss | N/A | 3 | N/A | Nov 1, 2021 |
| Jun 30, 2021 | -$0.21 | -$0.26 | -$0.27 - -$0.25 | +19.23% | Beat | N/A | 3 | N/A | Jul 29, 2021 |
| Mar 31, 2021 | -$0.24 | -$0.27 | -$0.28 - -$0.26 | +11.11% | Beat | N/A | 2 | N/A | May 3, 2021 |
| Dec 31, 2020 | -$0.47 | -$0.45 | -$0.49 - -$0.42 | -4.44% | Miss | N/A | 3 | N/A | Mar 10, 2021 |
| Sep 30, 2020 | -$0.27 | -$0.35 | -$0.36 - -$0.29 | +22.86% | Beat | N/A | 3 | N/A | Oct 29, 2020 |
| Jun 30, 2020 | -$0.31 | -$0.37 | N/A | +16.22% | Beat | N/A | N/A | N/A | Jul 30, 2020 |
| Mar 31, 2020 | -$0.40 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 12, 2020 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.57, after -$1.93 the year before. It was -$1.45 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.57 | N/A |
| Dec 31, 2024 | -$1.93 | N/A |
| Dec 31, 2023 | -$1.48 | N/A |
| Dec 31, 2022 | -$1.31 | N/A |
| Dec 31, 2021 | -$1.13 | N/A |
| Dec 31, 2020 | -$1.45 | N/A |
Earnings Calls
The 4 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 5,700 words across 5 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 5,684 | 5 | |
| 2025Q3 | Sep 30, 2025 | 4,792 | 3 | |
| 2025Q1 | Mar 31, 2025 | 4,509 | 4 | |
| 2024Q3 | Sep 30, 2024 | 7,042 | 4 |
2026Q2 Earnings Call
Opening remarks
Panna Sharma President and CEO Good morning, everyone, and thank you for joining us to discuss our second quarter 2026 results. As I have said before, AI and computationally driven approaches are now becoming central to how both large and emerging biopharma companies discover and develop drugs, but also how they allocate their resources and think about staffing their scientific teams. Today, we are at an inflection point that is actually accelerating not just for Lantern, but for how science itself will be conducted. And we are watching it happen in real trials with real patients at Lantern. The golden age of artificial intelligence in medicine is not beginning; it is actually accelerating. And this quarter, that idea has resulted in the development of a new company, Open Medicine AI. In August, we established Open Medicine AI as a separate company with commercial licenses and agreements with Lantern in place to take the AI data models to the next level. I will spend some real time on that today because I think it is the most consequential structural decision we have made since starting Lantern. But let me first walk you through what got us here. A clinical signal that sharpened into a defined patient population, a signal that was actually validated using big data, a European regulatory clearance in a challenging recurrent cancer and a valuable patent on a patient selection method — one of our most valuable assets, LP-184 — and an FDA cleared trial in triple negative breast cancer that is moving toward launch. All of these were backed by numerous observations in our trials: the LP-300 trial, the LP-184 trial, and even the LP-284 trial. What those observations were is that the mechanistic insights gained during our preclinical work actually have real-world parallels, and they could be the basis for meaningful activity in actual cancer patients. The remainder of 2026 is a defining year for Lantern Pharma, and especially as we launch into 2027. We have achieved clinical validation across multiple programs while establishing the foundation for our next phase of growth in both of our engines: our drug development engine and also now our AI engine. In addition, our mid-year financial results reflect highly disciplined execution with a 25% reduction in total operating expenses year over year even as we advanced multiple clinical programs through key inflection points and launched an entirely new company in one of the most promising and disruptive areas of AI in medicine. Our AI-driven clinical pipeline now encompasses multiple drug candidates across solid tumors, blood cancers, and now pediatric oncology, with a combined annual market potential estimated at over $15 billion.
Frequently Asked Questions About LTRN
When is Lantern Pharma's next earnings date?
Lantern Pharma's next earnings report is expected for Nov 17, 2026.
Did LTRN beat earnings estimates last quarter?
Yes. Lantern Pharma reported EPS of -$0.28 for the quarter ended Jun 30, 2026, above the -$0.38 estimate, a 26.32% surprise.
What EPS do analysts expect from LTRN next quarter?
The consensus EPS estimate for Lantern Pharma for the quarter ending Dec 31, 2026 is -$0.42 from 3 analysts.
How often does LTRN beat earnings estimates?
Lantern Pharma beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +14.98%.
LTRN pages: Overview, Earnings, Forecast, Financials, Competitors